Evolus Inc (NASDAQ:EOLS) Receives Consensus Rating of “Buy” from Analysts

Share on StockTwits

Shares of Evolus Inc (NASDAQ:EOLS) have received an average recommendation of “Buy” from the ten ratings firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $28.00.

A number of research analysts recently weighed in on the stock. ValuEngine upgraded shares of Evolus from a “hold” rating to a “buy” rating in a report on Thursday, July 18th. Wells Fargo & Co began coverage on shares of Evolus in a research note on Friday, June 28th. They issued a “market perform” rating and a $16.00 price target for the company. Mizuho reiterated a “buy” rating and issued a $30.00 price target on shares of Evolus in a research note on Thursday, September 5th. Barclays began coverage on shares of Evolus in a research note on Tuesday, June 11th. They issued an “underweight” rating and a $13.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Evolus from a “hold” rating to a “sell” rating in a research note on Thursday, August 15th.

Shares of EOLS stock traded up $0.27 during trading on Thursday, reaching $17.57. The company’s stock had a trading volume of 143,758 shares, compared to its average volume of 302,326. The company has a debt-to-equity ratio of 1.87, a current ratio of 5.01 and a quick ratio of 4.51. The company has a market capitalization of $484.91 million, a price-to-earnings ratio of -11.19 and a beta of 4.83. The stock’s 50-day moving average price is $16.22 and its 200 day moving average price is $19.10. Evolus has a 1-year low of $10.22 and a 1-year high of $30.25.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Monday, August 12th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.41). The company had revenue of $2.30 million for the quarter, compared to analysts’ expectations of $0.29 million. On average, sell-side analysts anticipate that Evolus will post -4.28 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA lifted its stake in Evolus by 8,877.3% in the first quarter. BNP Paribas Arbitrage SA now owns 1,975 shares of the company’s stock worth $45,000 after acquiring an additional 1,953 shares during the last quarter. Edge Wealth Management LLC purchased a new position in Evolus in the second quarter worth approximately $29,000. Ladenburg Thalmann Financial Services Inc. lifted its stake in Evolus by 2,224.0% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,324 shares of the company’s stock worth $34,000 after acquiring an additional 2,224 shares during the last quarter. Prime Capital Investment Advisors LLC purchased a new stake in shares of Evolus during the 2nd quarter worth approximately $44,000. Finally, Metropolitan Life Insurance Co NY purchased a new stake in shares of Evolus during the 1st quarter worth approximately $83,000. Institutional investors own 19.20% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Story: Current Ratio

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.